Amgen reported strong third-quarter results with a 23% year-over-year revenue increase and robust performance across multiple therapeutic areas. The positive guidance for 2024, progress in the pipeline, and strategic investments bolster investor confidence, likely driving the stock upwards in the short term. Despite some increased expenses due to acquisitions, the overall outlook remains optimistic.

[1]